Metabolic

Featured Article

Clinician Perspective: Examining the Link Between Antipsychotics and Diabetes

Clinician Perspective: Examining the Link Between Antipsychotics and Diabetes

Endocrinologist Kevin M. Pantalone, DO, and psychiatrist Christian Kohler, MD, discuss the risk associated with the use of antipsychotic medications in individuals with type 2 diabetes.

Latest Features

Clinician Perspective: Examining the Link Between Antipsychotics and Diabetes

Clinician Perspective: Examining the Link Between Antipsychotics and Diabetes

Endocrinologist Kevin M. Pantalone, DO, and psychiatrist Christian Kohler, MD, discuss the risk associated with the use of antipsychotic medications in individuals with type 2 diabetes.

Antidiabetic Drugs and Cardiovascular Risk: Expert Perspectives

Antidiabetic Drugs and Cardiovascular Risk: Expert Perspectives

Although many of the newer antidiabetic drugs have demonstrated favorable outcomes in clinical trials, some have also been associated with increased risk of adverse CV outcomes.

Semaglutide May Be Useful for Treating Obesity in People Without Diabetes

Semaglutide May Be Useful for Treating Obesity in People Without Diabetes

In combination with dietary and physical activity counseling, all semaglutide doses from 0.05-0.4 mg daily were tolerated and resulted in dose-related reductions in body weight among people with obesity without diabetes.

Cardiovascular Risk Factors in Cross-Sex Hormone Therapy: Expert Opinion

Cardiovascular Risk Factors in Cross-Sex Hormone Therapy: Expert Opinion

In a meta-analysis of cross-sex hormone therapy use in transgender individuals, researchers found that transgender women may have a greater risk for CVD mortality vs cisgender women in the general population.

Lowering LDL Cholesterol HIV: Pitavastatin vs Pravastatin

Lowering LDL Cholesterol HIV: Pitavastatin vs Pravastatin

Pitavastatin had greater low-density lipoprotein-lowering effects than pravastatin.

Fasting vs Nonfasting Lipid Values and Cardiovascular Risk: Q&A With Advisory Board Member, Eliot Brinton, MD

Fasting vs Nonfasting Lipid Values and Cardiovascular Risk: Q&A With Advisory Board Member, Eliot Brinton, MD

Eliot Brinton, MD, FAHA, FNLA, president and director of the Utah Lipid Center, discusses the benefits of fasting lipid profiles in predicting cardiovascular risk.

New Recommendation for Glucose-Lowering Drug Clinical Trials

New Recommendation for Glucose-Lowering Drug Clinical Trials

The International Hypoglycaemia Study Group now recommends that glucose levels lower than 3.0 mmol/L (54 mg/dL) be documented in clinical trials of glucose-lowering drugs.

Understanding Obesity's Role in Atrial Fibrillation

Understanding Obesity's Role in Atrial Fibrillation

The comorbid conditions of obesity and atrial fibrillation require better prevention and treatment strategies.

Preventing Heart Failure One Risk Factor at a Time

Preventing Heart Failure One Risk Factor at a Time

Avoiding 3 major risk factors for heart failure—hypertension, diabetes, and obesity—may reduce the likelihood of heart failure development.

Physical Activity for Diabetes: ADA Updated Guidelines

Physical Activity for Diabetes: ADA Updated Guidelines

Physical activity guidelines were updated for patients with type 2 diabetes, type 1 diabetes, and prediabetes.

Latest News

Effects of Liraglutide on Cardiovascular Events in Hypoglycemia

Effects of Liraglutide on Cardiovascular Events in Hypoglycemia

Investigators examined the association between hypoglycemia and cardiovascular outcomes and death.

Beta-Blockers Show Varied Effects on Hypoglycemic Mortality Risk in Diabetes

Beta-Blockers Show Varied Effects on Hypoglycemic Mortality Risk in Diabetes

Investigators examined the relationship between the use of β-blockers and incidence of hypoglycemia and risk for mortality in hospitalized patients with diabetes.

Empagliflozin, Liraglutide Reduce Cardiovascular Mortality Risk

Empagliflozin, Liraglutide Reduce Cardiovascular Mortality Risk

Investigators conducted a meta-analysis to compare the efficacy of SGLT2i, DPP-4i, and GLP-1 agonists for reducing cardiovascular outcomes.

ITCA 650 Shows Efficacy in Reducing Weight, HbA1c in Type 2 Diabetes

ITCA 650 Shows Efficacy in Reducing Weight, HbA1c in Type 2 Diabetes

The ITCA 650, a small titanium osmotic mini-pump, provides a subcutaneous infusion of exenatide over 3 or 6 months.

SGLT2 Inhibitor Use Linked to Lower Risk for Heart Failure, Death in Type 2 Diabetes

SGLT2 Inhibitor Use Linked to Lower Risk for Heart Failure, Death in Type 2 Diabetes

Regardless of presence of preexisting cardiovascular disease, SGLT2 inhibitors were associated with lower risk for death and heart failure.

Fenofibrate Improves Cholesterol Levels in Type 2 Diabetes

Fenofibrate Improves Cholesterol Levels in Type 2 Diabetes

To understand the mechanism underlying the benefit of fenofibrate on vascular complications in patients with type 2 diabetes, investigators assessed carotid intima thickness as a marker of subclinical atherosclerosis.

Plasma Methylglyoxal Levels Associated With CVD, Mortality in Type 2 Diabetes

Plasma Methylglyoxal Levels Associated With CVD, Mortality in Type 2 Diabetes

Investigators sought to determine whether methylglyoxal levels are associated with cardiovascular disease in type 2 diabetes.

Emotional Hyper-Reactivity and Cardiometabolic Risk in Remitted Bipolar Disorder

Emotional Hyper-Reactivity and Cardiometabolic Risk in Remitted Bipolar Disorder

Patients with remitted bipolar disorder and emotional hyper-reactivity also have significantly higher levels of low-grade inflammation, hypertension, and impaired glucose metabolism, indicating a higher risk for cardiometabolic dysfunction.

Cardiovascular Mortality in Individuals With Early-, Late-Onset Prediabetes

Cardiovascular Mortality in Individuals With Early-, Late-Onset Prediabetes

Investigators examined the frequency of cardiovascular vs noncardiovascular deaths in individuals who developed prediabetes that did not progress to diabetes.

Effect of Testosterone Replacement on Glycemic Control in Obese Men With Hypogonadism, T2D

Effect of Testosterone Replacement on Glycemic Control in Obese Men With Hypogonadism, T2D

Investigators examined the effect of testosterone replacement therapy on metabolic syndrome and vascular function in obese males with hypogonadism.

Sign Up for Free e-Newsletters